AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.3125
-0.0200 (-6.02%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.3325
Open0.3290
Bid0.3000 x 4000
Ask0.3500 x 2200
Day's Range0.3105 - 0.3290
52 Week Range0.2900 - 12.2000
Volume489,403
Avg. Volume3,258,065
Market Cap11.215M
Beta3.09
PE Ratio (TTM)N/A
EPS (TTM)-4.4380
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE12 days ago

    Aytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(TM) to Expand Company's Commercial-Stage Product Portfolio

    ENGLEWOOD, CO / ACCESSWIRE / June 13, 2018 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the Company has exclusively licensed Zolpimist™ (zolpidem tartrate oral spray) in the United States and Canada. Annual sales in the U.S. prescription sleep aid category were $1.8 billion over the 12-month period ending February 2018, approximately the same as the testosterone replacement prescription category.1 The Company believes that the addition of Zolpimist will complement ongoing Natesto selling efforts among primary care physicians and add another revenue-generating product to the Company's portfolio.

  • Why You Need To Look At This Factor Before Buying Aytu BioScience Inc (NASDAQ:AYTU)
    Simply Wall St.19 days ago

    Why You Need To Look At This Factor Before Buying Aytu BioScience Inc (NASDAQ:AYTU)

    For Aytu BioScience Inc’s (NASDAQ:AYTU) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. AYTU is exposedRead More...

  • ACCESSWIRElast month

    Wired News – Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial Hypertension

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Acceleron Pharma Inc. (NASDAQ: XLRN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XLRN as the Company's latest news hit the wire. On May 22, 2018, the Company announced that it has commenced the PULSAR Phase-2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), which is a chronic and life-changing disease that can lead to heart failure. Active-Investors.com is currently working on the research report for Aytu BioScience, Inc. (NASDAQ: AYTU), which also belongs to the Healthcare sector as the Company Acceleron Pharma.

  • ACCESSWIRElast month

    Aytu BioScience, Inc. to Present at the 8th Annual LD Micro Invitational Investor Conference

    ENGLEWOOD, CO / ACCESSWIRE / May 23, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, announced today that it will be presenting at the 8th Annual LD Micro Invitational investor conference on Tuesday, June 5th, at 9:00 AM PST / 11:00 AM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or ''Low T'') and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate-specific membrane antigen (PSMA) for prostate cancer detection and staging.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • ACCESSWIRElast month

    Aytu BioScience Provides Fiscal Third Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    ENGLEWOOD, CO / ACCESSWIRE / May 14, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • ACCESSWIRE2 months ago

    Aytu BioScience CEO Issues Letter to Shareholders

    ENGLEWOOD, CO / ACCESSWIRE / May 8, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has highlighted its progress of the company's commercial strategy in the below letter to shareholders. In response to multiple inquiries from interested stakeholders, I'm pleased to provide a short, high-level summary of the Company's progress as we continue launching Natesto in the U.S. while building our commercial capabilities and product portfolio. Since the Company's most recent communication we have made significant progress in both our execution in the field as well as with our patient reimbursement access through the introduction of the Natesto Support Program.

  • ACCESSWIRE2 months ago

    Aytu BioScience to Report Fiscal Third Quarter 2018 Results and Business Update

    ENGLEWOOD, CO / ACCESSWIRE / May 7, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the company will present its operational results for the fiscal third quarter 2018 on Monday, May 14, 2018, at 4:30 p.m. ET. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • ACCESSWIRE2 months ago

    Aytu BioScience Featured in Local ABC News Segment (VIDEO): "UM Doctors Test New Medication for Treating Men with Low Testosterone; Nasal Testosterone Gel doesn't Appear to have Negative Side Effects, Doctors Say."

    ENGLEWOOD, CO / ACCESSWIRE / May 3, 2018 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has been featured in a local ABC News segment presented by medical specialist anchor Kristi Krueger: "UM doctors test new medication for treating men with low testosterone. 'Doctors say there are two major side effects [to testosterone replacement therapy]. "One, it blocks the sperm production, especially for young men or men who wish to conceive in the future and are still interested in fertility and family building," said Dr. Ranjith Ramasamy, director of reproductive urology at the University of Miami Health System.' 'Ramasamy said testosterone therapy also blocks any natural testosterone production.

  • ACCESSWIRE3 months ago

    Aytu BioScience to Present at The MicroCap Conference on April 10th in New York City at the Essex House

    ENGLEWOOD, CO / ACCESSWIRE / April 3, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company") will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 10:30 am. ...

  • ACCESSWIRE3 months ago

    Aytu BioScience Announces Exercise of Underwriters' Over-Allotment Option

    ENGLEWOOD, CO / ACCESSWIRE / March 28, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in ...

  • ACCESSWIRE3 months ago

    Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting

    Post-hoc Data Analysis Demonstrates Natesto's Restoration of Normal Testosterone Levels in Hypogonadal Men While Maintaining Normal Levels of Estradiol (E2) and Dihydrotestosterone (DHT), Which Are Frequently ...

  • Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?
    Simply Wall St.4 months ago

    Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?

    Today I will take a look at Aytu BioScience Inc’s (NASDAQ:AYTU) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...

  • Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico
    PR Newswire4 months ago

    Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico

    ENGLEWOOD, Colo., March 7, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it has received registration in Mexico for the MiOXSYS System, from the Secretary of Health at Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).  The MiOXSYS System will be distributed exclusively through IMP Medica, a distributor of medical products to urologists, andrologists, and fertility centers throughout Mexico and in key markets in Latin America. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Regulatory licenses and registrations are critical to our efforts of effectively penetrating these new markets.

  • Aytu BioScience Announces Closing of $12,000,000 Public Offering
    PR Newswire4 months ago

    Aytu BioScience Announces Closing of $12,000,000 Public Offering

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of an aggregate of 19,520,000 shares of our Common Stock and Warrants to purchase an aggregate of 19,520,000 shares of Common Stock, at a public offering price of $0.45 per Class A Unit, and (ii) Class B Units consisting of 3,216 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 7,146,667 shares of Common Stock, and Warrants to purchase an aggregate of 7,146,667 shares of Common Stock, at a public offering price of $1,000 per Class B Unit.

  • Zynex Appoints New Independent Board Member
    PR Newswire4 months ago

    Zynex Appoints New Independent Board Member

    ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Joshua R. Disbrow to its Board of Directors and Audit Committee. Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. ("Aytu" NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology.  Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals ("Ampio", a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary "Luoxis").

  • Aytu BioScience Announces Pricing of $12,000,000 Public Offering
    PR Newswire4 months ago

    Aytu BioScience Announces Pricing of $12,000,000 Public Offering

    ENGLEWOOD, Colo., March 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the pricing of an underwritten public offering with expected total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of an aggregate of 19,520,000 shares of our Common Stock and Warrants to purchase an aggregate of 19,520,000 shares of Common Stock, at a public offering price of $0.45 per Class A Unit, and (ii) Class B Units consisting of 3,216 shares of our Series B Convertible Preferred Stock, with a stated value of $1,000, and convertible into an aggregate of 7,146,667 shares of Common Stock, and Warrants to purchase an aggregate of 7,146,667 shares of Common Stock, at a public offering price of $1,000 per Class B Unit.

  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire4 months ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S.  Robust Natesto prescription growth continued through January 2018, with total prescriptions reaching 1,094, their highest level to date and demonstrating 300% growth over the same month last year.  Additionally, for the three months ending January 31, 2018 Natesto prescriptions increased 12% over the three-month period ending October 31, 2017. Natesto total prescriptions for the month of January were 1,094, the highest monthly total recorded to date.

  • Benzinga4 months ago

    Moleculin Biotech's Volatility, Explained

    Moleculin Biotech Inc (NASDAQ: MBRX )’s good-news rally had a short life. The stock popped 55 percent Thursday after management announced a “breakthrough” discovery of a molecule capable of shutting down ...

  • Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswire4 months ago

    Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last year ENGLEWOOD, Colo. , Feb. 8, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life ...

  • Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update
    PR Newswire5 months ago

    Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Feb. 1, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal second quarter 2018 on Thursday, February 8, 2018, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire5 months ago

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , Jan. 16, 2018 /PRNewswire/ --   OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2017 performance ...

  • Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?
    Simply Wall St.6 months ago

    Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?

    Aytu BioScience Inc (NASDAQ:AYTU), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AYTURead More...

  • Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference
    PR Newswire6 months ago

    Aytu BioScience to Present at Biotech Showcase 2018 Investor Conference

    Aytu's management will present on Tuesday, January 9th at 9:30 AM PT in Yosemite-C (Ballroom level) and will be meeting with investors throughout the conference. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.